Zoetis ZTS
Healthcare · Drug Manufacturers - Specialty & Generic · Synthos Deep Dive · 2026-07-03
The Overview
Zoetis makes medicines, vaccines, and tests for animals — both pets (dogs, cats) and farm animals (cattle, pigs, chickens, fish). Think flea-and-tick pills, pet-allergy drugs, and livestock vaccines. It is the biggest company in the world at this, and it is a genuinely high-quality, very profitable business.
Here's the problem: the stock has fallen by more than half in the past year — from about $160 down to $75. That happened because pet owners, feeling the pinch, are visiting the vet less and skipping the pricey brand-name products where Zoetis makes the most money, and cheaper copycat competitors are moving in. So even a great company can be a stalled stock.
Is it cheap? Yes, on paper — you're paying about $12 for every $1 of annual profit, the lowest in five years. But cheap can get cheaper if the business keeps slowing, and right now management itself only expects sales to grow 2–5% this year. Our verdict is Watch: keep an eye on it, don't rush in. We'd want to see demand stabilize first.
Here's what our three scores mean in everyday terms:
- Downside Risk 5/10 (middle of the road). It's cheap and steady (the stock doesn't normally swing wildly), but it just proved it can crash, and it carries a moderate amount of debt.
- Growth Quality 5/10 (average). The quality (profit margins, returns) is elite, but the growth has stalled — so it nets out to average.
- Exponential Potential 3/10 (low). This is a mature market leader in a slow-growing field. Don't expect it to double quickly.
The one big worry: the slowdown in US pet spending might not be a temporary blip — if pet owners permanently trade down to cheaper products, Zoetis's most profitable business shrinks.
Putting a number on it: our fair-value estimate is $84 against a current price of $77.34 — real upside if our numbers are right.
Our summary metrics
Cheap now (12× trailing) & low beta 0.74, but a −53% 12-mo crash, decelerating demand & 1.8× net-debt/EBITDA.
Elite margins (71% GM, 62% ROE) but growth has stalled — FY26 organic revenue guided just 2–5%.
A mature
What does “fair value” mean?
Fair value is Synthos’s estimate of what one share is worth today, based on our model of the company’s future cash generation and the risks to it. It is not a price target or a prediction of where the stock trades next quarter — it’s the price where we think risk and reward are balanced. Above it, you’re paying for outcomes better than our base case; below it, the market is offering a margin of safety.
The model’s inputs and weightings are proprietary — they’re the product. What we publish is the output, plus an independent, public-math cross-check further down the page (“Check our number”) so you can judge it for yourself.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Exponential Potential
A mature
What could take this further than the base case — and where the market may be underpricing it. Full forward-growth and acceleration math in Deeper analysis, §4 below.
Clinical pipeline
Clinical-trial data for ZTS hasn’t been pulled yet — check back soon.
Deeper analysis
Technicals, fundamentals, valuation, and the full expert-claim evidence panel — the detail behind the numbers above.
Reference table
| Street consensus | $113 (high $160 / low $85; 1 Strong-Buy · 14 Buy · 16 Hold · 0 Sell — consensus "Hold") — context, not our anchor |
| Valuation | 12.4× trailing EPS · 10.9× FY26E · 10.1× FY27E · 8.0× FY30E · EV/S 4.1× · EV/EBITDA 9.6× |
| Technicals | Downtrend — $74.80, −53% off 52-wk high, below 50/200-DMA, RSI 34, −53% 12-mo (SPY +21%) |
| Conviction | Low — 0 expert voices, 0 traceable claims; the call rests entirely on fundamentals + quant |
| Position sizing | Watch-list; a starter ≤1–2% only for investors who want the falling-knife optionality — not a core buy yet |
What the experts actually said
No independent expert claims in the Synthos knowledge base yet for ZTS — this dive is fundamentals- and technicals-driven, not panel-driven.
Price & moving averages 12 months · 50 & 200-day averages · 52-week range
Solid line = price · dashed line = 50-day average · dotted line = 200-day average · the two thin horizontal lines mark the 52-week high and low. Price above both averages is an uptrend.
Data summary: last close $77.34, 2% above the 50-day average ($76), 26% below the 200-day average ($104) — a mixed trend. 51% below the 52-week high of $156, 8% above the 52-week low of $72.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Data summary: price $77.34 is currently inside the band (band $72–$79).
RSI (14) momentum gauge · 0–100
Above 70 (overbought zone, shaded) = overbought, below 30 (oversold zone, shaded) = oversold. Currently 53.
MACD 12 / 26 / 9 · trend & momentum
The MACD line crossing above the signal line (bars flip to the up color) = momentum turning up; crossing below (bars flip to the down color) = turning down. Bar height = the size of that gap.
Data summary: MACD is currently above its signal line by 0.28, positive momentum.
Relative performance vs S&P 500 & its sector (XLV (sector)), set to 100 a year ago
Solid = ZTS · dashed = S&P 500 · dotted = XLV (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
1. What it is
Zoetis (NYSE: ZTS) is the global leader in animal health — the research, development, manufacture, and sale of veterinary medicines, vaccines, diagnostics, and precision-livestock tools. It spun out of Pfizer in 2013 and has two ends of the barbell: companion animals (dogs, cats, horses — dermatology like Apoquel/Cytopoint, the Simparica parasiticide line, the Librela/Solensia monoclonal-antibody pain franchise, plus diagnostics) and livestock (cattle, swine, poultry, fish — vaccines, anti-infectives, medicated feed additives). Fiscal year ends December 31. Headquartered in Parsippany, NJ; ~13,800 employees; CEO Kristin Peck.
Revenue mix (FY2025, from filings):
- By reporting segment: United States $5.10B (55%) · International $4.25B (45%). The US is the higher-margin, more premium-product-weighted half — and precisely where the FY26 weakness is concentrated (Q1'26 US revenue −8%, International +10% organic).
- By species (FMP product segmentation, FY25): the file reports Cattle $1.49B, Swine $0.47B, Poultry $0.43B, Fish $0.29B, plus a large companion-animal bucket. Data caveat: FMP's FY25 species tags are mislabeled (it books ~$6.3B under "Horses," which is really the combined dog/cat companion-animal line — Zoetis's largest category by far). We flag this rather than repeat a bad number. Directionally: companion animal is the majority of revenue and the growth engine of the last decade; livestock is the steadier, lower-multiple base.
The strategic story management tells is a pipeline of "more than 12 potential blockbusters" across chronic kidney disease, oncology, cardiology, anxiety, and pet obesity, plus the pending acquisition of Neogen's animal-genomics business (expected 2H26) to extend livestock genomics. Whether that pipeline re-accelerates a stalled top line is the entire debate.
2. The expert thesis
There is no expert thesis to report. The Synthos knowledge base contains zero claims on Zoetis (total_claims: 0, net_bullish_voices: 0). None of our tracked voices — bullish or cautionary — has said anything traceable about ZTS.
That means two honest things:
1. We cite no claim_ids here because there are none. Anywhere this report reads as conviction, it is our own reading of the numbers, not a distilled expert panel.
2. The verdict is fundamentals- and quant-driven. For a name with no KB breadth we deliberately anchor conservatively on reported financials, live analyst estimates (FMP), management's own dated guidance (half-weighted, §9), and the technical/valuation picture — and we lean toward Watch rather than a high-conviction Buy or Avoid, because we lack the independent expert corroboration that would let us underwrite either extreme. The Street itself sits at Hold (16 Hold vs 15 Buy), consistent with that stance.
3. Synthos scores
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
| Score | 0–10 | The read |
|---|---|---|
| Downside Risk (lower = safer) | 5 · Moderate | Cheap (12.4× trailing, EV/EBITDA 9.6×) and low beta (0.74) argue safer; but a −53% 12-mo crash + max drawdown −70% from peak proves the realized downside, and net-debt/EBITDA 1.8× (up from ~1.2× after the debt-funded year) is moderate leverage. Balanced at 5. |
| Growth Quality | 5 · Average | The quality is elite — 71% gross margin, 42% EBITDA margin, 62% ROE, 22% ROIC, income quality ~1.0. But growth has stalled: revenue +2.3% FY25, Q1'26 organic flat, FY26 guided +2–5%. Elite margins × stalled growth = average composite. |
| Exponential Potential | 3 · Low | Mature #1 in a low-single-digit-growth category. No acceleration (2nd derivative is flat-to-negative); the multibagger case is absent. Cheap ≠ exponential. |
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. The cases bound the range; the scores above summarize them.
| Case | Key assumptions | Fair value |
|---|---|---|
| Bull | Demand stabilizes 2H26; Librela/dermatology re-accelerate; pipeline delivers; FY27E EPS reaches the high end ~$7.75 and the multiple re-rates back toward its historical ~15× as growth returns. | ~$112 (+50%) |
| Base (our anchor) | Guidance roughly holds — low-single-digit organic growth persists, FY27E EPS ~$7.35 (consensus), and the multiple stays de-rated at ~11.5× given the growth stall. | ~$84 (+12%) |
| Bear | US price-sensitivity is structural, generics + competition keep eroding the premium book, growth stays ~flat; FY27E EPS slips to ~$6.75 and the multiple compresses further to ~8.5×. | ~$58 (−22%) |
Synthos fair value = the base case, ~$84 (+12%), with the full $58–$112 span as the honest range. Our base sits below the Street's $113 consensus: the Street's average target still embeds a growth recovery we are not willing to underwrite without either demand stabilization in the price action or expert corroboration we don't have. Note the Street's own low target ($85) is right at our base, and the consensus rating is only Hold — the high targets are dragging the average up. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). ZTS is a high-quality compounder that has stopped compounding for now — and was never an exponential:
- Forward growth: revenue CAGR FY25→FY30E ~4.2% ($9.47B → $11.64B); EPS CAGR ~9.3% ($6.03 → $9.39) — the EPS line outpaces revenue only via buybacks and margin, not unit demand.
- Acceleration (the 2nd derivative) is negative: revenue growth decelerated from double-digits in 2021–22 to +8.3% (FY23) → +8.3% (FY24) → +2.3% (FY25), and Q1'26 organic was flat. Management guides FY26 organic revenue to just 2–5%. This is deceleration, not an inflection. Per our flagship philosophy we hunt forward next-exponentials with accelerating growth — ZTS is the opposite profile.
- Room to run: the animal-health TAM is real and defensively attractive (pet humanization, protein demand), but Zoetis is already the #1 player at ~$9.5B revenue in a market growing low-to-mid single digits. There is no small-cap-into-huge-TAM asymmetry here; a 3–5× would require multiple expansion and a demand renaissance, not category creation.
- Reinvestment runway: solid but ordinary — ~$0.62B/yr capex (6% of revenue), a growing dividend (payout ~34%), and bolt-on M&A (Neogen genomics). Capital is returned, not reinvested at exponential rates.
Exponential Potential: Low (3/10). Own ZTS, if at all, for eventual quality-compounder mean-reversion — not for a fast multibagger. The honest framing is that cheapness is the only thing pulling this above a 2; the growth signature does not support more.
5. Financials (real numbers — FMP annual/quarterly)
- Revenue: FY25 $9.47B, +2.3% (FY24 $9.26B, +8.3% on FY23 $8.54B). The deceleration is the headline. Q1'26 revenue $2.26B, +3% reported but flat organic — and US −8%.
- Quarterly trajectory: Q1'25 $2.22B → Q2 $2.46B → Q3 $2.40B → Q4 $2.39B → Q1'26 $2.26B. Sequentially soft; the growth engine has clearly downshifted.
- Margins (elite, and holding): gross 70.8% TTM, EBITDA 42.4%, operating ~37.6%, net 27.8% TTM. Best-in-class for the sector — the moat shows up in the P&L even as volumes soften.
- Returns on capital: ROE 62%, ROIC 21.8%, ROCE 27.3% — genuinely elite capital efficiency. This is why the business deserves a premium multiple when it grows.
- Earnings: net income $2.67B FY25 (+7.5%), EPS $6.03 vs $5.47. Q1'26 net income $601M, adjusted EPS $1.53 (adjusted for $45M of purchase-accounting/one-time items).
- Cash flow: operating CF $2.90B, capex −$0.62B, FCF $2.28B FY25 (FCF margin ~24%; FCF yield ~6.8%). Cash generation is strong and steady — the business is not broken, it's decelerating.
- Balance sheet: total debt $9.49B, cash $2.31B, net debt $7.18B, net-debt/EBITDA 1.8× — moderate, investment-grade (letter rating B+), interest coverage ~14.8×. Note leverage rose in FY25 (net debt $4.76B → $7.18B) as the company raised $2.27B of debt and bought back $3.24B of stock — aggressive repurchase into a falling price.
6. Valuation — priced in or room?
For the first time in years, ZTS is cheap on its own history: 12.4× trailing EPS, 10.9× FY26E, 10.1× FY27E, EV/EBITDA 9.6×, EV/Sales 4.1×, FCF yield ~6.8%. A company that historically traded at 25–35× now sits near 10×. The bull case is simply mean reversion: a 71%-gross-margin, 62%-ROE franchise rarely stays at 10× unless the market believes growth is permanently impaired.
The bear's retort is that the de-rating is the market correctly re-pricing a low-growth animal-health company — if organic growth is really 2–5%, a low-teens multiple is fair, not cheap, and PEG math (P/E ÷ growth) actually looks rich on organic units (trailing PEG ~1.5). The reverse-DCF read: at $74.80 the market is pricing roughly the guided low-single-digit organic growth in perpetuity with no re-acceleration — i.e. the stall is now the base case, and any stabilization is upside.
Street targets (context, not our anchor): consensus $113, high $160, low $85; rating Hold. Our $84 base is deliberately below consensus (right at the Street low) because we won't pay for a recovery we can't yet see and have no expert corroboration for. Not a value trap yet, but not the screaming bargain the raw 12× P/E implies either — fairly valued for the growth on offer.
7. Technicals (from the tech block)
- Trend: down. $74.80 sits below the 50-DMA ($86.24) and far below the 200-DMA ($117.33) — a clean downtrend, death-cross posture. MACD −3.2 (negative).
- Location: −53% off the 52-week high ($159.18), only +4% off the 52-week low ($71.86) — pinned near the lows. Max drawdown from peak −70%. This is a broken chart, not a base.
- Momentum: RSI(14) 34 — near oversold (<30) but not there; no bullish divergence to point to.
- Relative strength (the tell): ZTS −53% 12-mo vs SPY +20.6% and QQQ +30.3%; −36% 3-mo vs SPY +14%. Persistent, severe underperformance of both the market and the Nasdaq. The price action is unambiguously negative.
- Read: technicals do not confirm any bottom. A falling-knife name near 52-week lows with a death cross — cheapness is not a catalyst. Wait for the stock to reclaim the 50-DMA (~$86) or for demand to visibly stabilize before treating this as a turn.
8. Moat & competitive position
Zoetis's moat is real and multi-part: (1) the #1 scale position in a fragmented, R&D-and-regulation-gated industry; (2) a diversified portfolio across species and geographies that smooths any single product's decline; (3) branded franchises with vet loyalty (Simparica, Apoquel/Cytopoint, the Librela/Solensia mAb pain platform) and a direct vet-channel sales force; and (4) manufacturing and diagnostics breadth few peers match. The 71% gross margin and 62% ROE are the moat's fingerprints.
But the moat is being tested, not breached: US companion-animal demand is price-sensitive, generics have arrived on Convenia and Cerenia, and dermatology + parasiticides face intensifying competition (management's own words, Q1'26). Moat durability is high; near-term pricing power is visibly weaker than it was.
Peer set (FMP-supplied; market cap): the closest pure comp is Elanco (ELAN, $12.5B) — the other big animal-health pure-play — and diagnostics-adjacent IDEXX ($44B). The rest of the FMP peer list is broader healthcare, not direct comps: Regeneron ($67B), argenx ($58B), Becton Dickinson ($57B), Cencora ($58B), Takeda ($53B), Haleon ($43B), Cigna ($76B), Elevance ($91B). Against ELAN and IDEXX, Zoetis has the best margins and returns but, right now, similar or worse growth momentum — its premium multiple has compressed toward the group.
9. Management, capital allocation & guidance
- Capital allocation: shareholder-return-tilted — FY25 saw $3.24B of buybacks (into a falling stock) plus $0.89B of dividends (payout ~34%, yield ~2.75%), funded partly by $2.27B of new debt, which pushed net-debt/EBITDA to 1.8×. Aggressive repurchase near the lows is defensible if the business is sound, riskier if the stall deepens. Capex is a disciplined ~6% of revenue; the Neogen genomics acquisition (2H26) is the notable bolt-on.
- Insider activity: the sampled window (mid-June 2026) shows only routine director/officer equity awards and a new-officer Form 3 (grants and option holdings, no open-market discretionary sales) — no alarming insider selling signal, but also no conviction-signaling insider buying into the crash.
- Management's own guidance — the earnings-release track (half-weighted; they talk their own book). From the SEC 8-K (Q1'26 release, filed 2026-05-07), management revised FY2026 guidance: revenue $9.68–9.96B with organic operational revenue growth of 2–5%; organic operational adjusted-net-income growth 2–6%; adjusted diluted EPS $6.85–7.00. CEO Kristin Peck acknowledged plainly that "the first quarter unfolded in a more challenging operating environment than we anticipated. Pet owners demonstrated increased price sensitivity, resulting in a decline in veterinary visits and softer demand for premium innovative products… competition intensified across… dermatology and parasiticides." She points to a pipeline of "more than 12 potential blockbusters" and "a significant approval in a major market every year for the next several years." Honest weighting: this is management's self-interested framing (half-weight) — the candor about the demand miss is a credibility positive; the blockbuster/pipeline optimism is the book they must talk.
10. Catalysts & what to watch
- Next earnings: 2026-08-06 (Q2'26; Street EPS $1.85, revenue ~$2.51B). The key lines: US companion-animal organic growth (did the −8% stabilize?) and dermatology/Librela trajectory vs competition.
- US pet-demand stabilization: the single biggest swing factor — vet-visit volumes and premium-product mix.
- Competitive/generic erosion: Convenia/Cerenia generic impact and dermatology share vs new entrants.
- Pipeline delivery: the "12 blockbusters" (chronic kidney disease, oncology, cardiology, pet obesity) — any approval that re-accelerates the top line.
- Neogen genomics close (2H26): livestock-genomics extension; watch integration and accretion.
- Multiple re-rating: a reclaim of the 50-DMA (~$86) would be the first technical evidence the de-rating is over.
Thesis tripwires (what would change the call): two consecutive quarters of stabilizing/improving US organic growth would move us toward Buy; a further guidance cut, deepening US declines, or margin compression below ~40% EBITDA would move us toward Avoid.
11. Key risks
- Demand slowdown is structural, not cyclical (the core risk): if US pet-owner price sensitivity and trade-down persist, Zoetis's most profitable book (premium companion-animal innovation) shrinks — exactly what Q1'26 showed.
- Competitive & generic erosion: generics on Convenia/Cerenia and intensifying competition in dermatology and parasiticides directly hit the highest-margin franchises.
- No expert corroboration: with zero KB coverage we are underwriting on numbers alone — lower conviction on both the bull and bear tails, which is why the verdict is Watch, not Buy.
- Leverage crept up: net-debt/EBITDA rose to 1.8× as the company levered to buy back stock into a falling price; manageable, but less cushion than a year ago.
- Value-trap risk: cheap on trailing numbers can stay cheap (or get cheaper) if low-single-digit organic growth is the new normal — a low-teens multiple would then be fair, not a discount.
- Falling-knife technicals: near 52-week lows, below both moving averages, −53% 12-mo — no evidence of a bottom.
12. Verdict, position sizing & monitoring
Watch. Zoetis is a genuinely elite business — #1 in animal health, 71% gross margin, 62% ROE, 24% FCF margin — now at a 5-year-low 12× earnings after a −53% crash. That combination is tempting. But the crash reflects a real demand stall (US companion-animal −8% in Q1'26, generics and dermatology competition biting), management just cut FY26 organic growth to 2–5%, the chart is a falling knife below both moving averages, and we have zero expert coverage to corroborate a contrarian bull case. Cheapness without a catalyst is not enough for a Buy; a broken franchise it is not, so it is not an Avoid. It is a Watch — a quality name we want to own after demand stabilizes, not while the knife is still falling.
- Sizing: watch-list first. For investors who specifically want the deep-value / mean-reversion optionality, a starter ≤1–2% scaled in only on evidence of stabilization (a reclaim of the 50-DMA ~$86, or a Q2'26 US organic inflection) — not a core position today.
- Monitoring: re-underwrite on the §10 tripwires; formal re-score each earnings print. This verdict is logged as a tracked Synthos call as of 2026-07-03 at $74.80.
- Single biggest risk: the US pet-spending slowdown proving structural rather than cyclical — permanently shrinking the premium franchise.
Provenance & disclosures
- Traceability: 0 KB claims, breadth 0 — there is no expert coverage of ZTS in the Synthos knowledge base, so no
claim_ids are cited (none exist). This verdict is explicitly fundamentals- and quant-driven; any conviction language is our own reading of reported data, not a distilled panel. Fabricated conviction is structurally impossible (claim-ID reconciliation) — and here there is simply nothing to reconcile. - Data as-of: fundamentals 2026-03-31 (Q1'26) · estimates & prices 2026-07-03 · management guidance from the SEC 8-K Q1'26 release (filed 2026-05-07). Forward figures are analyst consensus (FMP) or management guidance, labeled as estimates.
- Data-quality flag: FMP's FY25 product-segmentation species tags are mislabeled (booking the dog/cat companion line under "Horses"); we flagged rather than repeated the bad figure. Segment revenue by US/International reporting segment is used instead.
- Management caveat: management's FY26 guidance is its own book, half-weighted by design; the candor about the Q1 demand miss is noted as a credibility positive.
- Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
- Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").